Product
Palbociclib
Aliases
6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, Ibrance®, IBRANCE, IBRANCE® (20 other aliases)
Name
palbociclib
Target
CDK 4 and 6
FDA Approved
Yes
Ema approved
Status
0
155 clinical trials
2 organizations
1 drug
4 abstracts
212 indications
1 document
Indication
Breast CancerIndication
Breast NeoplasmsIndication
Breast TumorsIndication
Ewing SarcomaIndication
Solid TumorsIndication
Rhabdoid TumorIndication
RhabdomyosarcomaIndication
NeuroblastomaIndication
MedulloblastomaIndication
Diffuse Intrinsic Pontine GliomaIndication
ReceptorsIndication
OestrogenIndication
GeneIndication
ERBB2Indication
Solid TumorIndication
Colorectal CancerIndication
Pancreatic Ductal AdenocarcinomaIndication
bioequivalenceIndication
ER-positive, HER2-negative breast cancerIndication
Renal Cell CarcinomaIndication
High-grade Serous Ovarian CancerIndication
PIK3CA MutationIndication
AdultIndication
Unresectable Solid TumorIndication
Hormone Receptor Positive TumorIndication
Ovarian CancerIndication
Estrogen Receptor-PositiveIndication
HER2-Negative Breast CancerIndication
HR+/HER2- Locally AdvancedIndication
cancerIndication
DuctalIndication
BreastIndication
Breast NeoplasmIndication
NSCLCIndication
Colorectal cancerIndication
KRAS Gene MutationIndication
Advanced Solid TumorIndication
Early Breast CancerIndication
Advanced and Metastatic Breast CancerIndication
HER2+/HR+ Breast CancerIndication
COVID-19Indication
Head and Neck CancerIndication
Colon CancerIndication
CancerIndication
ColonIndication
Squamous Cell Carcinoma of Head and NeckIndication
lung cancerIndication
Malignant NeoplasmIndication
Non-Hodgkin LymphomaIndication
Stage IV Non-Hodgkin LymphomaIndication
Histiocytic SarcomaIndication
Juvenile XanthogranulomaIndication
Langerhans Cell HistiocytosisIndication
Malignant GliomaIndication
Recurrent Childhood RhabdomyosarcomaIndication
EpendymomaIndication
Recurrent GliomaIndication
HepatoblastomaIndication
Recurrent Langerhans Cell HistiocytosisIndication
Recurrent Malignant Germ Cell TumorIndication
Recurrent Malignant Solid NeoplasmIndication
OsteosarcomaIndication
Recurrent rhabdoid tumorIndication
Soft Tissue SarcomaIndication
GliomaIndication
Malignant Germ Cell TumorIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
Soft Tissue Sarcoma AJCC v7Indication
Osteosarcoma AJCC v7Indication
Stage IV Soft Tissue Sarcoma AJCC v7Indication
Wilms tumorIndication
Breast Cancer Stage IVIndication
RadiotherapyIndication
SurgeryIndication
Breast Cancer, Stage IVIndication
Estrogen Receptor PositiveIndication
HER2/Neu NegativeIndication
Bone MetastasisIndication
Progesterone Receptor PositiveIndication
Metastatic Malignant Solid NeoplasmIndication
Hormone Receptor PositiveIndication
HER2 NegativeIndication
TumorIndication
SolidIndication
Pancreatic CancerIndication
MelanomaIndication
Stage IV Breast Cancer AJCC v8Indication
Locally AdvancedIndication
KRAS Mutant Non-Small Cell Lung CancerIndication
Low-grade serous ovarian carcinomaIndication
Pancreatic CarcinomaIndication
Stage IV Ovarian CancerIndication
Prostate CancerIndication
Gastrointestinal CancerIndication
Lung CancerIndication
Childhood EpendymomaIndication
Wilms TumorIndication
Recurrent Malignant GliomaIndication
Refractory Soft Tissue SarcomaIndication
Stage III Pancreatic CancerIndication
Stage IIIA Non-Small Cell Lung CancerIndication
Stage IIIB Non-Small Cell Lung CancerIndication
Stage IV Non-Small Cell Lung CancerIndication
Pancreatic Cancer Stage IVAIndication
SarcomaIndication
Cancer of Unknown PrimaryIndication
Bladder CancerIndication
Head and Neck Squamous Cell CarcinomaIndication
GlioblastomaIndication
lymphomaIndication
Non-HodgkinIndication
Multiple MyelomaIndication
Breast CarcinomaIndication
Advanced SarcomaIndication
Recurrent Ovarian CarcinomaIndication
Stage III Ovarian Cancer AJCC v8Indication
Breast cancerIndication
Progesterone Receptor Positive TumorIndication
MetastasisIndication
Locally Advanced Breast CancerIndication
BRCA2 mutationIndication
BRCA1 MutationIndication
Hormone-receptor-positive Breast CancerIndication
Recurrent DiseaseIndication
ER+ Breast CancerIndication
Recurrent B Acute Lymphoblastic LeukemiaIndication
Stage II Breast CancerIndication
Stage IIB Breast CancerIndication
Breast Cancer AJCC Stage IAIndication
Stage IIA Breast CancerIndication
Stage IIIA Breast CancerIndication
Stage IIIB Breast CancerIndication
Non-small Cell Lung Cancer MetastaticIndication
Non-small Cell Lung Cancer Stage IIIBIndication
ChordomaIndication
Mantle Cell LymphomaIndication
Triple-Negative Breast CancerIndication
Colorectal Cancer stage IV AJCC v8Indication
Stage IVA Colorectal Cancer AJCC v8Indication
Stage IVB Colorectal Cancer AJCC v8Indication
Stage IVC Colorectal Cancer AJCC v8Indication
CarcinomaIndication
Breast Cancer (HER2-positive)Indication
Adenocarcinoma of the LungIndication
mantle cell lymphomaIndication
B-cell LymphomaIndication
Squamous CellIndication
AdenocarcinomaIndication
Thyroid CancerIndication
Endometrial CancerIndication
Breast Cancer MetastaticIndication
Breast Cancer RecurrentIndication
Acute Lymphoblastic LeukemiaIndication
PediatricIndication
Lung Cancer Squamous CellIndication
HER2-negativeIndication
CPS-EG ScoreIndication
DCISIndication
CYP3A4*22Indication
Breast DiseasesIndication
EGFR gene amplificationIndication
EGFR gene mutationIndication
ERBB2 Gene AmplificationIndication
ERBB2 MutationIndication
ERBB3 gene mutationIndication
Erbb4 Gene MutationIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
HER2-Positive Breast CarcinomaIndication
LymphomaIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Solid Tumor Refractory to TreatmentIndication
RetinoblastomaIndication
small cell lung cancerIndication
Estrogen Receptor Positive TumorIndication
Metastatic Breast CancerIndication
Clear Cell Renal Cell CarcinomaIndication
Esophageal Squamous Cell CarcinomaIndication
NeoplasiaIndication
Hormone Receptor-positive Breast CancerIndication
Hormone Replacement TherapyIndication
Breast Neoplasm FemaleIndication
Ewing's SarcomaIndication
Breast Cancer Stage IIIndication
Breast Cancer Stage IIIIndication
Dedifferentiated LiposarcomaIndication
Metastatic Dedifferentiated LiposarcomaIndication
InoperableIndication
Locally Advanced or MetastaticIndication
ER-positive Breast CancerIndication
LiposarcomaDrug
PalbociclibIndication
Hepatocellular CarcinomaClinical trial
Treatment Patterns and Clinical Outcomes Among Indian Patients Receiving Palbociclib Combinations for HR+/HER2- Advanced/Metastatic Breast Cancer in Real World SettingsStatus: Completed, Estimated PCD: 2022-02-22
Clinical trial
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORSStatus: Active (not recruiting), Estimated PCD: 2024-06-24
Clinical trial
An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-09-16
Clinical trial
Real-World Utilization of Palbociclib as 1L Treatment in Canadian HR+/HER2-women Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of Amcenestrant (SAR439859), Administered Orally as Monotherapy, Then in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast CancerStatus: Active (not recruiting), Estimated PCD: 2027-12-29
Clinical trial
Comparative Assessment of Overall Survival in Medicare Patients With HR+/HER2- Metastatic Breast Cancer Treated With Palbociclib in Combination With Aromatase Inhibitor (AI vs. AI Alone)Status: Active (not recruiting), Estimated PCD: 2024-05-31
Clinical trial
A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-30
Clinical trial
A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies Assessed in a Real-World Non-Interventional Study (EUCHARIS)Status: Completed, Estimated PCD: 2023-11-02
Clinical trial
An Open Label, Balanced, Randomized, Two Treatments, Two Sequences, Two Periods, Single Dose, Crossover Bioequivalence Study of Palbociclib 125 mg Capsules (Iclos) and Ibrance (Palbociclib) 125 mg Capsules Pfizer in Healthy Subjects Under Fed ConditionStatus: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseStatus: Active (not recruiting), Estimated PCD: 2026-08-24
Clinical trial
A Multicenter, Open-label, Randomized, Phase 1/2 Study of Belzutifan in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2027-03-16
Clinical trial
A Phase I/IIa, First-in-human, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-06-18
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2023-09-29
Clinical trial
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch StudyStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Retrospective, Multicenter, Observational Study to Evaluate Real-World Effectiveness of Palbociclib Plus Endocrine Therapy in Japanese Patients With HR+/HER2- Advanced Breast Cancer in First Line or Second Line SettingsStatus: Completed, Estimated PCD: 2024-02-26
Clinical trial
A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF FULVESTRANT (FASLODEX (REGISTERED)). WITH OR WITHOUT PD-0332991 (PALBOCICLIB) +/- GOSERELIN IN WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE THERAPYStatus: Completed, Estimated PCD: 2014-12-05
Clinical trial
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ARV-471(PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI-CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)Status: Recruiting, Estimated PCD: 2028-08-28
Clinical trial
A Phase Ib/III Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2023-08-29
Clinical trial
A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-22
Clinical trial
A Phase 1 Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-tumor Activity of PF-07248144 in Participants With Advanced or Metastatic Solid Tumors.Status: Recruiting, Estimated PCD: 2025-05-09
Clinical trial
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsStatus: Active (not recruiting), Estimated PCD: 2028-05-30
Clinical trial
REAL-WORLD TUMOR RESPONSE OF PALBOCICLIB IN COMBINATION WITH AN AROMATASE INHIBITOR AS FIRST-LINE THERAPY IN PRE/PERIMENOPAUSAL WOMEN WITH METASTATIC BREAST CANCERStatus: Completed, Estimated PCD: 2021-12-09
Clinical trial
A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, MTD/RP2D, and Antitumor Activity of ARTS-021 as a Single Agent and in Combination Therapy in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
Observational Cohort Study of Patients With Hormone Receptor-positive Metastatic Breast Cancer Treated With Palbociclib (Ibrance(Registered)) as Part of the United Kingdom Ibrance (Registered) Patient Program (IPP); the Real Outcomes Ibrance (Registered) Study (ROIS)Status: Completed, Estimated PCD: 2021-03-04
Clinical trial
Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region Like Saudi Arabia, UAE and Other GCC Countries: A Retrospective Study (Treasure Study)Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 Alone and in Combination With Palbociclib in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerStatus: Completed, Estimated PCD: 2022-09-29
Clinical trial
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast CancerStatus: Completed, Estimated PCD: 2022-04-26
Clinical trial
A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced DiseaseStatus: Terminated, Estimated PCD: 2022-06-28
Clinical trial
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2021-09-24
Clinical trial
A First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Real-World Treatment Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as 1st Line Therapy in Metastatic Breast CancerStatus: Completed, Estimated PCD: 2021-09-01
Clinical trial
A Phase 1, Multi-site, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacokinetics, Safety and Preliminary Efficacy of Two Strengths of DARE-PDM1 (1% or 3%) Versus Placebo Among Women With Symptomatic Primary DysmenorrheaStatus: Active (not recruiting), Estimated PCD: 2023-09-23
Clinical trial
A Phase 1/1b Trial of MRTX849 in Combination With Palbociclib in Patients With Advanced Solid Tumors With KRAS G12C MutationStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a 1st Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South KoreaStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
PERFORM: An EPidEmiological, PRospective Cohort Study to Generate Real-world Evidence in Patients With HR+/HER2- Advanced Breast Cancer Treated in the First Line Setting as Per Current Standard Of Care With an EndocRine-based Palbociclib CoMbination TherapyStatus: Recruiting, Estimated PCD: 2028-04-03
Clinical trial
A Randomized, Multicenter, Open-Label, Two-Arm, Phase II, Neoadjuvant Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast CancerStatus: Completed, Estimated PCD: 2021-07-06
Clinical trial
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF PALBOCICLIB (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF PREVIOUSLY UNTREATED ASIAN POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) ADVANCED BREAST CANCERStatus: Active (not recruiting), Estimated PCD: 2020-08-31
Clinical trial
A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a Background of Hormonal Therapy in Patients With Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation Followed by a Randomized, Double-Blind, Placebo-controlled, Parallel Group Extension (PASTOR).Status: Completed, Estimated PCD: 2018-03-30
Clinical trial
Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine TherapyStatus: Completed, Estimated PCD: 2023-02-15
Clinical trial
Phase 2a Study of ZW25 in Combination With Palbociclib Plus FulvestrantStatus: Active (not recruiting), Estimated PCD: 2023-04-28
Clinical trial
A Multicenter, Open-label, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Efficacy of SIM0270 Alone or in Combination in Subjects With ER-positive, HER-2 Negative Locally Advanced or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent ThromboinflammationStatus: Withdrawn, Estimated PCD: 2022-10-01
Clinical trial
A TREATMENT PROTOCOL FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED PALBOCICLIB CLINICAL STUDIESStatus: Recruiting, Estimated PCD: 2026-04-19
Clinical trial
A Phase Ib/II Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination With Systemic Anti-cancer Agents in Patients With ER Positive Breast Cancer or Advanced Solid Tumors.Status: Recruiting, Estimated PCD: 2024-07-01
Abstract
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.Org: Gustave Roussy Cancer Center, CARIO - HPCA, Department of Genetics, Claudius Regaud Institute, Eugène Marquis Comprehensive Cancer Center,
Abstract
CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.Org: Breast Center, LMU University Hospital, Comprehensive Cancer Center Erlangen-EMN, Joint practice Wolfratshausen, Medical University of Brandenburg,
Abstract
Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG Pediatric MATCH trial Arm I (APEC1621I).Org: Department of Pediatrics, University of Colorado and Center for Cancer and Blood Disorders, Children’s Hospital Colorado, Aurora, CO, University of Michigan, Ann Arbor, MI, Mayo Clinic, Rochester, MN, Children's Oncology Group, Monrovia, CA, Univ of Southern California/Children's Oncology Group, Arcadia, CA, Texas Children's Cancer and Hematology Center, Houston, TX, St. Jude Children's Research Hospital, Memphis, TN, Seattle Children's Hospital, Seattle, WA, National Cancer Institute, Rockville, MD, Frederick National Laboratory for Cancer Research, Frederick, MD, Center for Biomedical Informatics & Information Technology, NCI, NIH, Bethesda, MD, MD Anderson Cancer Center, Houston, TX, Developmental Therapeutics Clinic, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, National Cancer Institute Center for Bioinformatics, Rockville, MD, Dana-Farber Cancer Institute, Boston, MA, Cancer Therapy Evaluation Program, NCI, Bethesda, MD, Texas Children's Cancer Center/Baylor College of Medicine, Houston, TX,
Clinical trial
Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) MelanomaStatus: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
Phase II Single-arm Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2023-05-29
Clinical trial
A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-02-28
Clinical trial
A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor (ASPIRE - WI231696)Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
PALbociclib in Advanced Breast Cancer: Therapy INtegrating locorEgional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2024-10-23
Clinical trial
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer PatientsStatus: Completed, Estimated PCD: 2022-10-13
Clinical trial
A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast CancerStatus: Completed, Estimated PCD: 2020-03-13
Clinical trial
Modular Phase 1B Hypothesis-Testing, Biomarker-Driven, Talazoparib Combination Trial (TalaCom)Status: Recruiting, Estimated PCD: 2025-09-03
Clinical trial
Multicenter, First-line Metastatic Open-label Prospective Phase II Trial Evaluating the Combination of Palbociclib (CDK 4/6 Inhibitor) and Hormone Therapy (Letrozole or Anastrozole) in Women With Luminal, HER2 Negative Advanced Breast Cancer: Evaluation of the Prediction of Individual Treatment Efficacy Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies (Quantum Optics).Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2024-03-11
Clinical trial
CIMER: Combined Immunotherapies in Metastatic ER+ Breast CancerStatus: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)Status: Active (not recruiting), Estimated PCD: 2021-04-30
Clinical trial
A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid TumorsStatus: Completed, Estimated PCD: 2017-11-01
Clinical trial
Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment TrialStatus: Recruiting, Estimated PCD: 2026-08-26
Clinical trial
A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2022-04-29
Clinical trial
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer With Durable Disease Control: A Randomized Low-intervention Phase II Trial of the AIO Working Groups Breast Cancer and Quality of LifeStatus: Recruiting, Estimated PCD: 2027-01-10
Clinical trial
Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle GenesStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid MalignanciesStatus: Completed, Estimated PCD: 2021-10-15
Clinical trial
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HT Driven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2021-04-30
Clinical trial
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 TrialStatus: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)Status: Completed, Estimated PCD: 2023-02-22
Clinical trial
Targeted Agent and Profiling Utilization Registry (TAPUR) StudyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Clinical trial
A Phase 1B Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Combination of Encorafenib, Binimetinib and Palbociclib in Patients With BRAF-mutant Metastatic Melanoma (The CELEBRATE Study)Status: Recruiting, Estimated PCD: 2024-12-04
Clinical trial
Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
Harnessing Olaparib, Palbociclib and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (HOPE)Status: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.Status: Not yet recruiting, Estimated PCD: 2025-09-01
Clinical trial
Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent GlioblastomaStatus: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
Randomised Phase II Study of Induction Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA SuppressionStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2021-08-04
Clinical trial
Phase I/II Safety and Efficacy Study of Autophagy Inhibition With Hydroxychloroquine to Augment the Antiproliferative and Biological Effects of Pre-Operative Palbociclib Plus Letrozole for Estrogen Receptor-Positive and HER2-Negative Breast CancerStatus: Completed, Estimated PCD: 2024-04-17
Clinical trial
A Proof of Concept Study to Explore Safety and Efficacy of Tri-therapy Approach in Advanced/Metastatic NSCLC and Retrospectively Assess the Ability of Integrated Genomics and Transcriptomics to Match Patients to the CombinationStatus: Terminated, Estimated PCD: 2022-12-29
Clinical trial
Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2018-06-25
Clinical trial
PAveMenT: Phase Ib Study of Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal CancersStatus: Active (not recruiting), Estimated PCD: 2021-08-23
Clinical trial
Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase InhibitorStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2020-02-04
Clinical trial
Perioperative Analysis of Binimetinib and Palbociclib in RAS-Driven TumorsStatus: Withdrawn, Estimated PCD: 2025-09-30
Clinical trial
Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast CarcinomaStatus: Completed, Estimated PCD: 2018-05-01
Clinical trial
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-02-01
Clinical trial
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
Optimal Dosing of Oral Anticancer Drugs in Older Adults With Cancer: a Randomized Pilot Study.Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2, International, Multicenter, Open-labeled, Randomized Trial of PAlbociclib and Fulvestrant vs. Standard Oral Capecitabine In Patients With Hormone Receptor (HR)+ / HER2- Advanced Breast Cancer and Documented Endocrine ResistanceStatus: Terminated, Estimated PCD: 2021-04-30
Clinical trial
A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase1 Study at Stanford of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast CancerStatus: Completed, Estimated PCD: 2018-08-15
Clinical trial
A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast CancerStatus: Completed, Estimated PCD: 2020-08-28
Clinical trial
Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"Status: Completed, Estimated PCD: 2020-08-24
Clinical trial
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Status: Recruiting, Estimated PCD: 2026-12-20
Clinical trial
A Phase 1 Dose Escalation and Expansion Open-label, Multicenter, Study of OP-1250 in Combination With the CDK4/6 Inhibitor Palbociclib in Adult Subjects With Advanced or Metastatic HR-positive, HER2-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for SurgeryStatus: Terminated, Estimated PCD: 2023-12-06
Clinical trial
A Phase I/II Study of Palbociclib, Letrozole and T-DM1 in Trastuzumab Refractory Estrogen Receptor Positive (ER+) and HER2 Positive Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2020-03-12
Clinical trial
Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 GenotypeStatus: Withdrawn, Estimated PCD: 2027-03-01
Clinical trial
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-11-01
Clinical trial
Molecular Analysis for Combination Therapy Choice (ComboMATCH)Status: Recruiting, Estimated PCD: 2030-07-01
Clinical trial
A Phase II Trial of Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY)Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Single Arm Phase II Study to Evaluate Efficacy of T-DM1 With Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast CancerStatus: Completed, Estimated PCD: 2022-12-22
Clinical trial
MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CCND1, 2, 3 AmplificationStatus: Active (not recruiting), Estimated PCD: 2021-03-09
Clinical trial
Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined With Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors With Retinoblastoma DeficiencyStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK PathwayStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CDK4 or CDK6 AmplificationStatus: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast CancerStatus: Completed, Estimated PCD: 2023-01-03
Clinical trial
A Pilot Study of IMMUNe mOdulation in Early Stage Estrogen Receptor Positive Breast Cancer Treated With neoADjuvant Avelumab, Palbociclib, and Endocrine Therapy: The ImmunoADAPT StudyStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
International,Multicenter,Randomized,Open-label, Phase II to Evaluate the Efficacy and Safety of Continuation of Palbociclib+2nd Line Endocrine Therapy in HR+/HER2- ABC Patients Who Had Clinical Benefit During 1st Line Palbociclib.Status: Completed, Estimated PCD: 2022-11-30
Clinical trial
Comparing Oral Drug Dosing Strategies in Older Patients With Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) StudyStatus: Not yet recruiting, Estimated PCD: 2028-08-31
Clinical trial
Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)Status: Active (not recruiting), Estimated PCD: 2024-11-01
Clinical trial
Avelumab, Palbociclib and Axitinib in in Treatment Naive Metastatic Clear Cell Renal Cell Carcinoma.Status: Withdrawn, Estimated PCD: 2026-08-31
Clinical trial
Non-Interventional, National Study Of Real-World Evidence In Estrogen Receptor Positive, Her2 Negative Metastatic Breast Cancer Patients Treated With Palbociclib During a 2.5 Years Follow-Up PeriodStatus: Recruiting, Estimated PCD: 2024-03-25
Clinical trial
Impact of Age and Comorbidities on Treatment Outcomes of First-line Treatment With Palbociclib in Combination With an Aromatase Inhibitor (AI) in Patients Diagnosed With HR+/HER2 - Metastatic Breast Cancer - Danish Non-Interventional StudyStatus: Completed, Estimated PCD: 2024-04-19
Clinical trial
CDK4/6 Inhibitor Palbociclib Combined With Afatinib as Second-line Treatment for Advanced Squamous Carcinoma of the Esophagus or Gastroesophageal Junction Progressed on at Least First-line Chemotherapy: a Phase 2 TrialStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncerStatus: Completed, Estimated PCD: 2019-03-28
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyStatus: Terminated, Estimated PCD: 2022-12-30
Clinical trial
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ERStatus: Withdrawn, Estimated PCD: 2023-04-25
Clinical trial
Patterns of Prescribing and Monitoring of PalbociclibStatus: Completed, Estimated PCD: 2016-12-30
Clinical trial
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601)Status: Completed, Estimated PCD: 2022-12-22
Clinical trial
A Randomized, Open-label, Parallel-group Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in Early ER+/HER2- Breast CancerStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Randomised Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast CancerStatus: Completed, Estimated PCD: 2021-12-23
Clinical trial
Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®Status: Completed, Estimated PCD: 2021-04-12
Clinical trial
Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing SarcomaStatus: Completed, Estimated PCD: 2022-12-15
Clinical trial
Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2038-12-31
Clinical trial
A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-06-30
Clinical trial
Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant or an Aromatase Inhibitor and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse SurgeryStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
REVERT- Breast Cancer: Phase 1b/2 Study of the Addition of STAT3 Inhibitor TTI-101 to Reverse Resistance to Palbociclib or Ribociclib Plus Aromatase Inhibitor or Fulvestrant Therapy for Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerStatus: Completed, Estimated PCD: 2024-04-25
Clinical trial
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerStatus: Completed, Estimated PCD: 2022-01-18
Clinical trial
Official Title A Randomized Phase 2 Trial With a Safety Lead-In to Evaluate Palbociclib Versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated LiposarcomaStatus: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
A Phase 1b Study of Palbociclib, Letrozole and Venetoclax in ER and BCL-2 Positive Locally Advanced or Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Phase II Study of the Combination of Pembrolizumab, Letrozole, and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated LiposarcomaStatus: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Single-Arm, Prospective, Open Clinical Study of Palbociclib for Backline Treatment of Advanced Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2026-01-15
Document
DailyMed Label: IbranceOrganization
U.S. PharmaceuticalsOrganization
Pfizer Laboratories Div Pfizer Inc